Skip to main content
AAPL+0.64%MSFT+1.07%NVDA+0.64%GOOGL+0.80%AMZN+1.46%SPCX+1.27%TSM+0.81%AVGO+3.64%META+0.81%TSLA+0.74%LLY-2.33%WMT-0.13%AMD+5.31%SKHY-0.11%JPM-1.77%BRK-B-2.07%MU+1.55%V-0.37%JNJ-2.15%XOM-3.97%MA-0.37%ASMLa+1.94%ABBV-2.33%COST-1.21%1398.HK-0.79%0700.HK-5.82%KO-0.71%CVX-4.74%PG-0.83%CSCO+2.18%0939.HK-0.24%ORCL-0.97%3988.HK-0.36%GE+0.52%BAC-1.07%HD-0.40%1816.HK-26.17%0857.HK-2.43%UNH-10.21%1288.HK-1.64%PM-0.85%0005.HK-2.03%NVS-2.46%HSBA.L-2.00%INTC-0.91%MS-1.29%AMAT+0.88%AP2d+2.23%AZN-1.93%TXN-1.16%AUDJPY-1.58%AUDUSD-1.47%EURAUD+0.95%AUDCAD-0.92%AUDCHF-0.90%GBPAUD+0.88%AUDNZD-0.88%NZDJPY-0.72%GBPJPY-0.70%CHFJPY-0.68%CADJPY-0.67%EURJPY-0.65%USDCHF+0.60%NZDUSD-0.59%GBPUSD-0.57%USDCAD+0.57%AUDSGD-0.56%EURUSD-0.52%AUDDKK-0.51%GBPTRY+0.41%AUDNOK-0.40%USDZAR+0.33%GBPHKD+0.32%NZDMXN+0.32%USDMXN+0.32%USDTHB+0.30%GBPMXN-0.28%EURZAR+0.24%GBPZAR+0.21%USDTRY+0.21%USDNOK+0.19%USDILS+0.16%CHFNOK+0.14%USDJPY-0.13%USDSEK+0.13%USDPLN+0.12%USDCNH-0.12%EURCNH-0.12%EURNOK+0.11%NOKJPY-0.10%EURHKD-0.09%USDDKK+0.08%CHFSEK+0.08%GBPSGD-0.08%EURCHF+0.07%SGDJPY+0.07%EURNZD+0.06%EURGBP+0.05%EURSGD-0.05%NZDSGD+0.05%EURSEK+0.05%NZDCAD-0.05%EURCZK+0.04%EURPLN+0.04%USDCOP-0.04%EURCAD+0.03%USDSGD+0.03%GBPCAD-0.03%CADCHF+0.03%PLNJPY-0.03%NZDCHF-0.02%CHFSGD-0.02%GBPCHF+0.02%GBPNZD+0.02%USDHKD-0.01%EURDKK0.00%UKOIL+0.52%W1-0.51%XNGUSD-0.46%C1-0.41%XPTUSD-0.38%USOIL+0.32%HG1-0.31%S1-0.22%GAUUSD-0.11%XAUUSD-0.11%COTTON+0.08%XAGUSD+0.06%BTCUSD-3.46%ETHUSD+57.77%USDTUSD-0.01%XRPUSD+52.58%SOLUSD+57.55%TRXUSDT+0.77%ZECUSDT-6.58%XMRUSDT-1.65%DOGEUSD+55.95%LINKUSD-3.12%XLMUSD-3.50%BCHUSDT-3.41%LTCUSD+47.50%UNIUSD-2.84%SUIUSD-2.76%TONUSD+59.18%HBARUSDT-4.95%TAOUSDT-2.97%AAVEUSD-3.45%ONDOUSDT-5.16%ICPUSDT-1.57%DOTUSDT-3.63%WLDUSDT-3.57%ARBUSDT-5.49%ATOMUSDT-2.24%INJUSDT-7.58%STXUSDT-2.75%PYTHUSDT-0.96%TIAUSDT-2.82%FETUSDT-4.16%JUPUSDT+0.63%SEIUSDT-4.48%GRTUSDT-3.22%OPUSDT-2.63%IOTAUSDT-2.46%POLUSDT-1.89%WIFUSDT-2.25%AXSUSDT-2.76%EOSUSDT-3.95%IMXUSDT-3.36%FARTCOINUSDT-6.28%GALAUSDT-1.65%DYDXUSDT-2.47%ORDIUSDT-2.25%NOTUSDT+0.86%RONINUSDT-2.92%AAPL+0.64%MSFT+1.07%NVDA+0.64%GOOGL+0.80%AMZN+1.46%SPCX+1.27%TSM+0.81%AVGO+3.64%META+0.81%TSLA+0.74%LLY-2.33%WMT-0.13%AMD+5.31%SKHY-0.11%JPM-1.77%BRK-B-2.07%MU+1.55%V-0.37%JNJ-2.15%XOM-3.97%MA-0.37%ASMLa+1.94%ABBV-2.33%COST-1.21%1398.HK-0.79%0700.HK-5.82%KO-0.71%CVX-4.74%PG-0.83%CSCO+2.18%0939.HK-0.24%ORCL-0.97%3988.HK-0.36%GE+0.52%BAC-1.07%HD-0.40%1816.HK-26.17%0857.HK-2.43%UNH-10.21%1288.HK-1.64%PM-0.85%0005.HK-2.03%NVS-2.46%HSBA.L-2.00%INTC-0.91%MS-1.29%AMAT+0.88%AP2d+2.23%AZN-1.93%TXN-1.16%AUDJPY-1.58%AUDUSD-1.47%EURAUD+0.95%AUDCAD-0.92%AUDCHF-0.90%GBPAUD+0.88%AUDNZD-0.88%NZDJPY-0.72%GBPJPY-0.70%CHFJPY-0.68%CADJPY-0.67%EURJPY-0.65%USDCHF+0.60%NZDUSD-0.59%GBPUSD-0.57%USDCAD+0.57%AUDSGD-0.56%EURUSD-0.52%AUDDKK-0.51%GBPTRY+0.41%AUDNOK-0.40%USDZAR+0.33%GBPHKD+0.32%NZDMXN+0.32%USDMXN+0.32%USDTHB+0.30%GBPMXN-0.28%EURZAR+0.24%GBPZAR+0.21%USDTRY+0.21%USDNOK+0.19%USDILS+0.16%CHFNOK+0.14%USDJPY-0.13%USDSEK+0.13%USDPLN+0.12%USDCNH-0.12%EURCNH-0.12%EURNOK+0.11%NOKJPY-0.10%EURHKD-0.09%USDDKK+0.08%CHFSEK+0.08%GBPSGD-0.08%EURCHF+0.07%SGDJPY+0.07%EURNZD+0.06%EURGBP+0.05%EURSGD-0.05%NZDSGD+0.05%EURSEK+0.05%NZDCAD-0.05%EURCZK+0.04%EURPLN+0.04%USDCOP-0.04%EURCAD+0.03%USDSGD+0.03%GBPCAD-0.03%CADCHF+0.03%PLNJPY-0.03%NZDCHF-0.02%CHFSGD-0.02%GBPCHF+0.02%GBPNZD+0.02%USDHKD-0.01%EURDKK0.00%UKOIL+0.52%W1-0.51%XNGUSD-0.46%C1-0.41%XPTUSD-0.38%USOIL+0.32%HG1-0.31%S1-0.22%GAUUSD-0.11%XAUUSD-0.11%COTTON+0.08%XAGUSD+0.06%BTCUSD-3.46%ETHUSD+57.77%USDTUSD-0.01%XRPUSD+52.58%SOLUSD+57.55%TRXUSDT+0.77%ZECUSDT-6.58%XMRUSDT-1.65%DOGEUSD+55.95%LINKUSD-3.12%XLMUSD-3.50%BCHUSDT-3.41%LTCUSD+47.50%UNIUSD-2.84%SUIUSD-2.76%TONUSD+59.18%HBARUSDT-4.95%TAOUSDT-2.97%AAVEUSD-3.45%ONDOUSDT-5.16%ICPUSDT-1.57%DOTUSDT-3.63%WLDUSDT-3.57%ARBUSDT-5.49%ATOMUSDT-2.24%INJUSDT-7.58%STXUSDT-2.75%PYTHUSDT-0.96%TIAUSDT-2.82%FETUSDT-4.16%JUPUSDT+0.63%SEIUSDT-4.48%GRTUSDT-3.22%OPUSDT-2.63%IOTAUSDT-2.46%POLUSDT-1.89%WIFUSDT-2.25%AXSUSDT-2.76%EOSUSDT-3.95%IMXUSDT-3.36%FARTCOINUSDT-6.28%GALAUSDT-1.65%DYDXUSDT-2.47%ORDIUSDT-2.25%NOTUSDT+0.86%RONINUSDT-2.92%
IN

Incyte Corporation (INCY)

NASDAQ • Healthcare

$117.8
-$1.29 (-1.1%)
Market closed

Last close at November 18, 2026 at 21:00 UTC

Open$118.77
Day Range$117.73 - $120.99
Avg. Volume (3M)1.7M
Market Cap$24B
P/E Ratio56.1
52 Week Range
$89.25$132.6
Next EarningsIn 82 daysFeb 9, 2027

Metrics Over Time

Where the Money Goes

Q3 2026
Revenueeverything earned$1.5B100%
Gross Profitminus cost of goods$1.4B93%

In plain terms: out of every $100 in revenue, Incyte Corporation currently loses $50.

Fundamentals & Financials

Revenue (TTM)
$6B
Net Income (TTM)
$403.4M
EPS (TTM)
$2.1
ROA (TTM)
5.54%
Current Ratio
3.84

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

+35.1%Q2 2026$1.81
+43.7%Q3 2026$3.09
+8.4%Q4 2026-$3.6
Next

Feb 9

in 82 daysQ1 2027

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q4 2026
Beat +8.4%

Incyte beat revenue expectations in the third fiscal quarter of 2026, based on preliminary results reported October 29, 2026, with revenue up 14.0% to about $1.6 billion, rising from $1.366 billion a year ago, and topping the $1.465 billion estimate (+6.3%). The quarter’s sales mix remained heavily concentrated in the United States, where revenue rose 13.8% to roughly $1.4 billion, while Europe increased 7.0% to about $107 million. Profitability was reflected in gross profit of about $1.4 billion alongside a gross margin of 93.0%. Cash flow was a notable swing point, with negative operating cash flow of roughly $675 million. Consensus for the next period calls for EPS of $1.89 on revenue of $1.533 billion.

View full earnings history

About Incyte Corporation

Incyte Corporation develops and markets prescription therapies in biotechnology, with revenue of $5.1 billion in FY2025. Listed on the NASDAQ as INCY, the company combines commercial oncology and hematology drugs with a clinical pipeline and global marketing operations built around therapies it develops itself.

Name
Incyte Corporation
CEO
William J. Meury
Industry
Healthcare
Year Founded
1991
Employees
2,844

Today's Snapshot

AI-generated

INCY closed 1.1% below yesterday's close, in line with a weaker sector. Incyte hired Babar Bashir, a clinical-development executive, to lead blood-cancer research.

Trading Volume

Below 10d avg (1.4M)

1.2M

vs S&P 500 Today

Underperforming Market

-0.82%

Updated: November 18, 2026 at 21:25 UTC

Technical Indicators

2 Buy3 Neutral3 Sell
INCY appears balanced with mixed signals: short-term moving averages are slightly bearish while the longer-term averages remain supportive, leaving the stock in a neutral consolidation range. Momentum and RSI are near center, and the MACD is modestly positive but indecisive, while the ADX indicates a lack of trend conviction. Volatility is muted and the pivot sits above the current price, offering a near-term reference. Negative on-balance volume is a concern but does not dominate the technical picture. Technical takeaway: Neutral — conflicting moving averages and weak trend strength keep indicators balanced.
All signals
  • EMA (5 indicators)$110.50 - $119.67
    Sell
  • RSI (14)47.66
    Neutral
  • Stochastic %K (14, 3, 3)55.05
    Neutral
  • MACD Level (12, 26)0.68
    Neutral
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.